NEW YORK, February 6, 2018 /PRNewswire/ --
According to a reportby Grand View Research, the global medical cannabis market is projected to reach a value of USD 55.8 billion by 2025. After the elections of 2016, Washington D.C. along with 28 states has
Starting January 1st 2018, the state of California has started legal sales of cannabis products for recreational use. Tom Adams, Editor-in-Chief at Arcview Market Research and Principal Analyst at BDS Analytics explained: "Our data shows positive indicators across the board for the legal cannabis industry, in North America and around the globe… The passage of the 2016 ballot initiatives and continued maturation of the existing Adult-Use markets are the primary drivers of the growth this year. That's nothing compared to what we can expect in 2018 and beyond from Nevada's tourism, and California and Canada planning to launch Adult-Use sales in 2018."
Helix TCS Inc. (OTCQB: HLIX) just earlier today the company announced breaking news that, "along with its investment partner Rose Capital, acquired all of the outstanding preferred stock of Bio-Tech Medical Software, Inc. (or BioTrackTHC). This investment represents approximately 18.5% of BioTrackTHC's outstanding capital stock, on an as-converted to common basis. In addition, Helix CEO Zac Venegas will join BioTrackTHC's board.
"As we continue to execute our strategy of offering integrated operating services to the legal cannabis industry, we are excited to forge a stronger relationship with BioTrackTHC and work towards providing our clients with ways to operate with greater efficiency, security, compliance, and profitability," stated Mr. Venegas.
Since its founding in 2015, Helix continues to grow in scale and scope in the legal cannabis industry, operating in the security, transportation and compliance sectors. In 2016, it acquired Cannabase, the industry's oldest electronic wholesale marketplace.
"We are impressed with BioTrackTHC's growth and geographic footprint for seed-to-sale systems. Furthering our relationship with BioTrackTHC is an important step in our finding ways to support the technology and data capabilities of all of our business lines, including Cannabase," stated Venegas.
Helix TCS, Inc. is a premier provider of integrated operating environment solutions for the legal cannabis industry. Helix provides a proprietary software suite and partnership platform to the legal cannabis industry, helping clients manage inventory and supply costs and bespoke monitoring and transport solutions. Helix provides clients in the legal cannabis industry high standard security operations, including transportation, armed and unarmed guarding, training, investigation, and special services.
United Cannabis Corporation (OTCQB: CNAB) is a biotechnology company dedicated to the development of phyto-therapeutic based products supported by patented technologies for the pharmaceutical, medical, and industrial markets. Recently, the company announced that it has established a Limited Partnership between the Company, LASCO Manufacturing Limited (LASCO) and United Cannabis' Jamaican Partner, Cannabinoid Research & Development Co. Ltd. LASCO, one of the leading dry blend beverage companies in Jamaica, reported revenue of $56.2 million in 2017, with products exported to 22 countries throughout the Caribbean, Central and South America, Canada, United Kingdom, and the United States.The Company also announced that it has signed an exclusive License Agreement (the "Agreement") with LASCO to produce the Company's CBD water and other Bio Nutrient Medicinals in the form of Capsules, Sublinguals, Roll-ons, and Balms for the English-speaking Caribbean and Central America, excluding Mexico.
Innovative Industrial Properties, Inc. (NYSE: IIPR) is a self-advised Maryland corporation focused on the acquisition, ownership and management of specialized industrial properties leased to experienced, state-licensed operators for their regulated medical-use cannabis facilities. On December 18, 2017, the company announced that it closed on the previously announced acquisition of the property located at 5900 West Greenhouse Drive in Willcox, Arizona, which comprises approximately 358,000 square feet of greenhouse and industrial space. The Pharm is one of the largest wholesalers of medical-use cannabis in the state of Arizona. Concurrent with the closing of the purchase, the Company entered into a long-term, triple-net lease agreement with a subsidiary of The Pharm, which intends to continue to operate the property as a medical-use cannabis cultivation and processing facility in accordance with Arizona medical-use cannabis regulations.
Cannabis Sativa, Inc. (OTCQB: CBDS) is engaged in the licensing of cannabis related intellectual property, marketing and branding for cannabis based products and services, operation of cannabis related technology services, and ancillary business activities. CBDS licenses the "hi" and "White Rabbit" brands, holds a U.S. patent on the Ecuadorian Sativa strain of Cannabis, owns patent pending and trade secret formulas and processes, offers the hi benefits discount pharmacy card, and operates subsidiaries including: PrestoDoctor, Wild Earth Naturals, and iBudtender. On December 4, 2017, the company announced that its subsidiary, PrestoDoctor, is expanding its online medical marijuana recommendation services into New York. PrestoDoctor currently serves patients via both their online platform and with dispensary kiosks operating in California and Nevada and will now extend their online services to patients located in the State of New York.
Vitality Biopharma, Inc. (OTCQB: VBIO) is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. On January 17, 2018, the company announced it has submitted an orphan drug designation request for VITA-100 to the U.S. Food & Drug Administration. Upon approval, VITA-100 would be designated as an orphan drug for the treatment of pediatric ulcerative colitis (UC), a form of pediatric inflammatory bowel disease. The U.S. Orphan Drug Act (ODA) of January 1983 is meant to encourage development of drugs for rare diseases, and review by the FDA's Office of Orphan Products Development can expedite the evaluation and eventual market approval of products that demonstrate significant promise for the treatment of these conditions. Vitality Biopharma's gut-targeted cannabosides enable delivery of THC without psychoactivity or intoxication, which may enable more widespread use of cannabinoids for treatment of pediatric digestive disorders. The Company has already completed studies that demonstrate the efficacy of cannabosides for treatment of preclinical models of colitis. Cannabosides were able to reduce weight loss, decrease damage to the colon, and markedly improve gastrointestinal health compared to the placebo controls.
Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
For further information: Media Contact: email@example.com , +1-877-601-1879 Url: http://www.FinancialBuzz.com
Subscribe to our Free Newsletters!